Serotonergic dysregulation in bipolar disorders: A literature review of serotonergic challenge studies

Bipolar Disorders

Volumn 4, Issue 6, 2002, Pages 347-356

  Sobczak, S ^a   Honig, A ^a   van Duinen, M A ^a   Riedel, W J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Biological vulnerability; Bipolar disorder; Cortisol; Mood; Prolactin; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 5 HYDROXYTRYPTOPHAN; AMITRIPTYLINE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; FENFLURAMINE; HALOPERIDOL; HYDROCORTISONE; IPSAPIRONE; LITHIUM; PROLACTIN; PSYCHOTROPIC AGENT; SEROTONIN; TRYPTOPHAN; VALPROIC ACID;

AGE; BIPOLAR DISORDER; BRAIN FUNCTION; DEPRESSION; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; GASTROINTESTINAL DISEASE; HORMONE RESPONSE; HUMAN; MANIA; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; PROLACTIN RELEASE; PROVOCATION TEST; PSYCINFO; REVIEW; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SUICIDAL BEHAVIOR; WEIGHT REDUCTION;

BIPOLAR DISORDER; DATABASES, BIBLIOGRAPHIC; HUMANS; NEUROSECRETORY SYSTEMS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS;

EID: 0036932079     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2002.01217.x     Document Type: Review

References (100)

1. Quattrone A, DiRenzo GF, Schettini G, Tedeschi G, Scopacasa F. Increased plasam prolactine levels induced in rats by d-fenfluramine: relation to central serotonergic stimulation. Eur J Pharmacol 1978; 49: 163-167.
2. Abel KM, Cleare AJ. Peripheral hormonal responses to d-fenfluramine as a probe of central serotonergic function in humans. Psychopharmacology 1999; 142: 68-72.
3. Cleare AJ, Murray RM, O'Keane V. Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects. Neuropsychopharmacology 1996; 14: 349-354.
4. Goekoop JG. De regulatie van de hypothalamus-hypofyse-bijnier-as in de pathogenese van depressieve stoornissen. Acta Neuropsychiatrica 1998; 10: 1-6.
5. Nurnberger JI Jr, Berrettini W, Simmons-Alling S, Lawrence D, Brittain H. Blunted ACTH and cortisol response to afternoon tryptophan infusion in euthymic bipolar patients. Psychiatry Res 1990; 31: 57-67.
6. Cleare AJ, Forsling M, Bond AJ. Neuroendocrine and hypothermic effects of 5-HT1A receptor stimulation with ipsapirone in healthy men: a placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 23-32.
7. Stahl SM, Hauger RL, Rausch JL, Fleishaker JC, Hubbell-Alberts E. Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol 1993; 16: S19-S31.
8. Murakami Y, Kato Y, Kabayama Y, Tojo K, Inoue T, Imura H. Involvement of growth hormone (GH)-releasing factor in GH secretion induced by serotoninergic mechanisms in conscious rats. Endocrinology 1986; 119: 1089-1092.
9. Chihara K, Arimura A, Schally AV. Effect of intraventricular injection of dopamine, noreprinephrine, acetylcholine, and 5-hydroxytryptamine on immunoreactive somatostatin release into rat hypophyseal portal blood. Endocrinology 1979; 104: 1656-1662.
10. Di Renzo G, Amoroso S, Taglialatela M et al. Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. Eur J Pharmacol 1989; 162: 371-373.
11. Van de Kar LD, Lorens SA, Urban JH, Bethea CL. Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion. Neuropharmacology 1989; 28: 299-305.
12. McNeilly AS. Prolactin. In: Lightman SL, Everitt BJ eds. Neuroendocrinology. Cambridge: Blackwell Scientific Publications, 1986.
13. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215-235.
14. Riedel WJ, Klaassen T, Griez E, Honig A, Menheere PPCA, van Praag HM. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood. J Psychopharmacol 2002; 26: 358-367.
15. Coccaro EF, Siever LJ, Klar HM et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive-aggressive behaviour. Arch Gen Psychiatry 1989; 46: 587-599.
16. Mann JJ, McBride PA, Brown RP et al. The relationship between central and peripheral serotonin indices in depressed and suicidal psychiatric inpatients. Arch Gen Psychiatry 1992; 49: 442-446.
17. Abel KM, O'Keane V, Murray RM, Cleare AJ. Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression. Psychoneuroendocrinology 1997; 22: 539-548.
18. Cleare AJ, Bond AJ. The effect of tryptophan depletion and enhancement on subjective and behavioural aggression in normal male subjects. Psychopharmacol Berl 1995; 118: 72-81.
19. Lucey JV, O'Keane V, Butcher G, Clare AW, Dinan TG. Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. Br J Psychiatry 1992; 161: 517-521.
20. Yatham LN, Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sci 1993; 53: 447-463.
21. Wirz Justice A, Puhringer W. Increased platelet serotonin in bipolar depression and hypomania. J Neural Transm 1978; 42: 55-62.
22. Marazziti D, Lenzi A, Cassano GB. Serotoninergic dysfunction in bipolar disorder. Pharmacopsychiatry 1991; 24: 164-167.
23. Leake A, Fairbairn AF, McKeith IG, Ferrier IN. Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatry Res 1991; 39: 155-165.
24. Prange AJ Jr, Wilson IC, Lynn CW, Alltop LB, Stike-leather RA. L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974; 30: 56-62.
25. Price LH, Charney DS, Delgado PL, Heniger GR. Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology 1990; 100: 3-12.
26. Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994; 35: 121-127.
27. Ginns EI, Ott J, Egeland JA et al. A genome-wide search for chromosomal loci linked to bipolar affective disorder in the Old Order Amish. Nat Genet 1996; 12: 431-435.
28. Kunugi H, Hattori M, Kato T et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997; 2: 457-462.
29. Oruc L, Verheyen GR, Furac I et al. Association analysis of the 5-HT2C receptor and 5-HT transporter genes in bipolar disorder. Am J Med Genet 1997; 74: 504-506.
30. Bellivier F, Leboyer M, Courtet P et al. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry 1998; 55: 33-37.
31. Lesch KP, Gross J, Franzek E, Wolozin BL, Riederer P, Murphy DL. Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biol Psychiatry 1995; 37: 215-223.
32. Shapira B, Lerer B, Kindler S et al. Enhanced serotonergic responsivity following electroconvulsive therapy in patients with major depression. Br J Psychiatry 1992; 160: 223-229.
33. Lerer B, Gillon D, Lichtenberg P, Gorfine M, Gelfin Y, Shapira B. Interrelationship of age, depression, and central serotonergic function: evidence from fenfluramine challenge studies. Int Psychogeriatr 1996; 8: 83-102.
34. Lichtenberg P, Shapira B, Blacker M, Gropp C, Calev A, Lerer B. Effect of fenfluramine on mood: a double-blind placebo-controlled trail. Biol Psychiatry 1992; 31: 351-356.
35. Kasper S, Vieira A, Schmidt R, Richter P. Multiple hormone responses to stimulation with d,1-Fenfluramine in patients with major depression before and after antidepressive treatment. Pharmacopsychiatry 1990; 23: 76-84.
36. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium treatment and serotoninergic function. Neuroendocrine and behavioral responses to intravenous tryptophan in affective disorder. Arch Gen Psychiatry 1989; 46: 13-19.
37. Price LH, Malison RT, McDougle CJ, Pelton GH, Heniger GR. The neurobiology of tryptophan depletion in depression: effects of intravenous tryptophan infusion. Soc Biol Psychiatry 1998; 43: 339-347.
38. Ansseau M, Doumont A, Thiry D, Geenen V, Legros JJ. Interest of 5-hydroxytryptophan (5-HTP) as a neuroendocrine marker in depressive illness. A negative report. Acta Psychiatr Belg 1983; 83: 50-56.
39. Maes M, Calabrese J, Jayathilake K, Meltzer HY. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res 1997; 71: 67-76.
40. Anand A, Charney DS, Delgado PL, McDougle CJ, Heniger GR, Price LH. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 1994; 151: 1626-1629.
41. Price LH, Malison RT, McDougle CJ, McCance Katz EF, Owen KR, Heninger GR. Neurobiology of tryptophan depletion in depression: effects of m-chlorophenylpiperazine (mCPP). Neuropsychopharmacology 1997; 17: 342-350.
42. Golden RN, Ekstrom D, Brown TM et al. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry 1992; 149: 1168-1175.
43. Kapitany T, Schindl M, Schindler SD et al. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 1999; 88: 75-88.
44. Rowland NE, Carlton J. Neurobiology of an anorectic drug: fenfluramine. Prog Neurobiol 1986; 27: 13-62.
45. Goodwin GM, Murray CL, Bancroft J. Oral D-fenfluramine and neuroendocrine challenge: problems with the 30 mg dose in men. J Affect Disord 1994; 30: 117-122.
46. Coccaro EF, Kavoussi RJ, Oakes M, Cooper TB, Hauger R. 5-HT-2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fefluramine challenge in physically healthy human subjects. Psychopharmacology 1996; 126: 24-30.
47. Coccaro EF, Siever LJ, Kourides IA, Adan F, Campbell G, Davis KL. Central serotoninergic stimulation by fenfluramine challenge does not affect plasma thyrotropin-stimulating hormone levels in man. Neuroendocrinology 1988; 47: 273-276.
48. Thakore JH, O'Keane V, Dinan TG. d-Fenfluramine-induced prolactin responses in mania: evidence for serotonergic subsensitivity. Am J Psychiatry 1996; 153: 1460-1463.
49. Muhlbauer HD. The influence of fenfluramine stimulation on prolactin plasma levels in lithium long-term-treated manic-depressive patients and healthy subjects. Pharmacopsychiatry 1984; 17: 191-193.
50. Mannel M, Muller-Oerlinghausen B, Czernik A, Sauer H. 5-HT brain function in affective disorder. d,1-fenfluramine-induced hormone release and clinical outcome in long-term lithium/carbamazepine prophylaxis. J Affect Disord 1997; 46: 101-113.
51. Muhlbauer HD, Muller-Oerlinghausen B. Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man. J Neural Transm 1985; 61: 81-94.
52. Yatham LN. Prolactin and cortisol responses to fenfluramine challenge in mania. Biol Psychiatry 1996; 39: 285-288.
53. Lichtenberg P, Shapira B, Gillon D et al. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res 1992; 43(2): 137-146.
54. Mitchell P, Smythe G, Parker G et al. Hormonal responses to fenfluramine in depressive subtypes. Br J Psychiatry 1990; 57: 551-557.
55. Charney DS, Heninger GR, Reinhard JF Jr, Sternberg DE, Hafstead KM. The effect of IV L-tryptophan on prolactin, growth hormone, and mood in healthy subjects. Psychopharmacol Berl 1982; 78: 138-143.
56. Power AC, Cowen PJ. Neuroendocrine challenge tests. assessment of 5-HT function in anxiety and depression. Mol Aspects Med 1992; 13: 205-220.
57. Westenberg HG, van Praag HM, de Jong JT, Thijssen JH. Postsynaptic serotonergic activity in depressive patients: evaluation of the neuroendocrine strategy. Psychiatr Res 1982; 7: 361-371.
58. Price LH, Charney DS, Delgado PL, Heninger GR. Serotonin function and depression: neuroendocrine and mood responses to intravenous L-tryptophan in depressed patients and healthy comparison subjects [see comments]. Am J Psychiatry 1991; 148: 1518-1525.
59. Deakin JF, Pennell I, Upadhyaya AJ, Lofthouse R. A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology 1990; 101: 85-92.
60. Van Praag HM, Lemus C, Kahn R. Hormonal probes of central serotonergic activity: do they really exist? Biol Psychiatry 1987; 22: 86-98.
61. van Vliet IM, Slaap BR, Westenberg HG, Den Boer JA. Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur Neuropsychopharmacol 1996; 6: 103-110.
62. den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5- hydroxytryptophan administration in panic disorder. Psychiatr Res 1990; 31: 267-278.
63. Van Praag HM, Korf J, Lequin RM. An unexpected effect of 1-5-hydroxytryptophan-ethyl-ester combined with a peripheral decarboxylase inhibitor on human serum prolactin. Psychopharmacol Commun 1976; 2: 369-378.
64. Takahashi S, Kondo H, Yoshimura M, Ochi Y, Yoshimi T. Growth hormone responses to administration of L-5-hydroxytryptophan (L-5-HTP) in manic-depressive psychoses. Folia Psychiatr Neurol Jpn 1973; 27: 197-206.
65. Meltzer HY, Uberkoman-Wiita B, Robertson A, Tricou BJ, Lowy M. Enhanced serum cortisol response to 5-hydroxytryptophan in depression and mania. Life Sci 1983; 33: 2541-2549.
66. Meltzer HY, Umberkoman Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. I. Enhanced response in depression and mania. Arch Gen Psychiatry 1984; 41: 366-374.
67. Meltzer HY, Perline R, Tricou BJ, Lowy M, Robertson A. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis, and depressive symptoms. Arch Gen Psychiatry 1984; 41: 379-387.
68. Meltzer HY, Lowy M, Robertson A, Goodnick P, Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. III. Effect of antidepressants and lithium carbonate. Arch Gen Psychiatry 1984; 41: 391-397.
69. Meltzer HY, Maes M. Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol Psychiatry 1994; 35: 316-323.
70. Anderson IM, Cowen PJ. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology 1992; 106: 428-432.
71. Yatham LN, Shiah IS, Lam RW, Tam EM, Zis AP. Hypothermic, ACTH, and cortisol responses to ipsapirone in patients with mania and healthy controls. J Affect Disord 1999; 54: 295-301.
72. Yatham LN. Buspirone induced prolactin release in mania. Biol Psychiatry 1994; 35: 553-556.
73. Lesch KP, Wiesmann M, Hoh A et al. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 1992; 106: 111-117.
74. Lesch KP, Rupprecht R, Poten B et al. Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biol Psychiatry 1989; 26: 203-205.
75. Shiah IS, Yatham LN, Lam RW, Tam EM, Zis AP. Cortisol, hypothermic, and behavioral responses to ipsapirone in patients with bipolar depression and normal controls. Neuropsychobiology 1998; 38: 6-12.
76. Mann JJ, McBride PA, Malone KM, DeMeo M, Keilp J. Blunted serotonergic responsivity in depressed inpatients. Neuropsychopharmacology 1995; 13: 53-64.
77. Goodall IM, Cowen PJ, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology 1993; 112: 461-466.
78. Fischbein DH, Lozovsky D, Jaffe JH. Impulsivity, aggression and neuroendocrine responses to serotonergic stimulation in substance abusers. Biol Psychiatry 1989; 25: 1049-1066.
79. Carboni E, di Chiara G. Serotonin release estimated by transcortical dialysis in freely-moving rats. Neuroscience 1989; 32: 637-645.
80. Dinan TG, Scott LV. The influence of cortisol on spontaneous and 5-HT stimulated prolactine release in man. J Basic Clin Physiol Pharmacol 1996; 7: 45-56.
81. Stahl SM. Neuroendocrine markers of serotonin responsivity in depression. Prog Neuro-Psychopharmacol Biol Psychiat 1992; 16: 655-659.
82. Gilbert F, Stahl SM, Tricklebank M. Characterization of the 5-HT receptor subtype mediating ACTH release in the rat. Br J Pharmacol; 91: 495P.
83. Post RM, Weiss SRB. Kindling and stress sensitization. In: Young LT, Joffe RT eds. Bipolar Disorder. Biological Models and their Clinical Application, 1st edn. New York: Marcel Dekker Inc. 1997: 93-126.
84. Malone, KM, Corbitt, EM, Li, S, Mann, JJ. Prolactin response to fenfluramine and suicide attempt lethality in major depression. Br J Psychiatry 1996; 168: 324-329.
85. Coccaro EF, Kavoussi RJ. Neuropsychopharmacologic challenge in biological psychiatry. Clin Chem 1994; 40: 319-327.
86. Coccaro EF, Klar H, Siever LJ. Reduced prolactine response to fenfluramine challenge in personality disorder patients is not due to deficiency of pituitary lactotrophs. Biol Psychiatry 1994; 36: 344-354.
87. Coccaro EF, Silverman JM, Klar HM, Horvath TB, Siever LJ. Familial correlates of reduced central serotonergic system function in patients with personality disorders. Arch Gen Psychiatry 1994; 51: 318-324.
88. Van der Does AJW. The effect of tryptophan depletion on mood and psychiatric symptoms: review. J Affect Disord 2001; 58(2): 200-202.
89. Amamoto T, Sarai K. On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5-HTP in patients with depression. Hiroshima J Med Sci 1976; 25: 135-140.
90. McCann UD, Seiden LS, Rubin LJ, Ricaurte GA. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. J Am Med Ass 1997; 278: 666-672.
91. Manji HK, Hsiao JK, Risby ED, Oliver J, Rudorfer MV, Potter WZ. The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. Arch Gen Psychiatry 1991; 48: 505-512.
92. Sobczak S, Honig A, Riedel WJ. Acute Tryptophan Depletion in bipolar disorders; literature review and directives for further research. Acta Neuropsychiatrica 2000; 12: 69-72.
93. Cleare AJ, Bond AJ. Does central serotonergic function correlate inversely with aggression? A study using d-fenfluramine in healthy subjects. Psych Res 1997; 69: 89-95.
94. O'Keane CV, O'Hanlon M, Webb M, Dinan T. D-fenfluramine / prolactine response throughout the menstrual cycle: evidence for an estrogen-induced alteration. Clin Endocrin 1991; 34: 289-292.
95. Fitzgerald M, Malone K, Li S et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psych 1997; 54: 556-558.
96. Klaassen T, Riedel WJ, van Someren A, Deutz NE, Honig A, van Praag HM. Mood effects of 24-hour tryptophan depletion in healthy first-degree relatives of patients with affective disorders. Biol Psychiatry 1999; 46: 489-497.
97. Cappiello A, Sernyak MJ, Malison RT, McDougle CJ, Heninger GR, Price LH. Effects of acute tryptophan depletion in lithium-remitted manic patients: a pilot study. Biol Psychiatry 1997; 42: 1076-1078.
98. Newman ME, Shapira B, Lerer B. Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. Int J Neuropsychopharmacol 1998; 1: 49-69.
99. Sobizan S, Honig A, Nicolson NA, Riedel WJ. Effects of acute Trytophan Depletion on mood and cortisol in first-degree relatives of type I and type II bipolar patients and healthy matched controls. Neuropsychopharmacolgy 2002; 28(2): (in press).
100. Sobizan S, Honig A, Van Duinen MA, Riedel WJ. Mood, prolactin and cortisol responses following intravenous 1-tryptophan challenge, evidence for serotonergic vulnerability in first-degree relatives of bipolar patients. Int J Neuropsychopharmacolgy 2000; 28(3): (in press).